Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
IBIO - Tabaksplant vaccine en protein productie
Volgen
In early stages hier. Plant based vaccine and drug production. Tobacco plant with dna injection used to quickly produce vaccins and other agents. "iBio, Inc – based in Newark, Del., engages in the development and commercialization of plant-based biotherapeutics (biosimilars, orphan biologics) and vaccines. Utilizing proprietary iBioLaunch™ technology the company aims to leverage its technology platform to provide these biotherapeutics in a safe, efficacious, reliable, and importantly, inexpensive manner. For more background on the company, see the FAQ section of the website, which is (surprisingly) detailed and informative. In the iBioLaunch platform, the DNA sequence to be produced (protein, antibody, vaccine, etc.) is inserted into the leaves via specially designed vectors and the new DNA expressed independently from the plant's own chromosomes (the plant is not transgenic). This ultimately leads to large quantities of biomass producing relatively large amounts of the desired protein (hundred milligram quantities of protein per 1 kg of biomass) that are subsequently purified by standard techniques to give the desired therapeutic. Vaccine Development: The vaccine market has traditionally been viewed as a low-margin business, but IBIO’s platform has the potential to take significant market share due to its low cost (10%-15% of animal cell / virus cultures). Given that plant-based systems have seen success in similar clinical trials (Medicago), IBIO’s lead candidates are de-risked in my opinion, and I anticipate that IBIO will announce favorable results in the H5N1 trial later this year. Furthermore, IBIO’s agreement (pdf) with Fiocruz for the use of yellow fever vaccine was a positive development, and we expect additional partners to come on board and fund further trials. IBIO plans to bring on partners to further the influenza (H1N1, H5N1 if successful) programs (government funding is a likely source, BARDA etc.). In addition, IBIO has successfully produced Hookworm (pdf) vaccine antigen, and is collaborating with the Sabin Vaccine Institute on this project." The iBioLaunch platform eliminates the need to culture cells under sterile conditions, removes uncertainty about yield consistency for large volumes of production, and, subject to regulatory approval, could deliver vaccine doses for emergency use against pandemic and bioterrorism threats in weeks rather than the months necessary with the use of engineered or attenuated virus strains. iBIO-Form 13D's of Late Insiders Locking up 55% of Float here www.sec.gov/Archives/edgar/data/11029... www.sec.gov/Archives/edgar/data/10533... www.sec.gov/Archives/edgar/data/14084... Last o One representing 36% while above 2 have 19% combined-Total of 55% now in insider hands Eastern Capital Limited beneficially owns 23,744,000 shares of the Issuer common stock, representing 36.0% of the Issuer outstanding common stock. Eastern Capital Limited has shared voting and dispositive power of the shares it beneficially owns with its parent, Portfolio Services Ltd. and Kenneth B. Dart. iBIO and CYTK->Both backed by Eastern Capital -June 2013 iBio Adds Chinese Patent For Anthrax Antibody -Jan 2011www.businesswire.com/news/home/201101... The 2011 news mentioned since its getting an 2013 update about a 170mln BLR investment in Brasil starting in 2014. The ministry will also invest BLR $ 170 million in the construction of the first national factory of organic products made from plant cell technology unprecedented in the country, in Ceará. "Biotechnology is part of the future in health care and Brazil has prospect of global platforms. Several states are putting technology platforms - Rio de Janeiro, Ceará, Paraná. Projects are not isolated, are within a national strategy," said Secretary of Science, Technology and Strategic Inputs, Carlos Gadelha. The new plant, which will use as raw carrot and tobacco, involves a partnership between Fiocruz and the Israeli company Protalix, the American Fraunhofer Center for Molecular Biotechnology and iBio Inc. This was also the first biotech vegetable-based which obtained registration the Food and Drug Administration (FDA) and the National Agency for Sanitary Surveillance (ANVISA), worldwide. Should start operating at full steam in 2016. The new pole Fiocruz will be installed in the city of Eusebio near Fortaleza (Ceará) and construction starts from 2014.A factory will initially produce drugs for rare diseases as Taliglucerase Alfa Recombinant Human, for Gaucher disease, and the first vaccine the world from a plant, yellow fever. The production process from the extraction plant is a novelty in the country. The technology ensures higher security than the biological produced from viruses and bacteria. Produces fewer side effects and less resistance facing the human body which receives the treatment. Moreover, it requires less investment. "Ceará is very happy to help correct regional inequalities in the country's time to celebrate because we see investing in Brazil and seeing possibilities," said state governor Cid Gomes. (Information Agency of Brazil)finviz.com/quote.ashx?t=ibio
Van April IBIO april GE alliance awarded contract to design new plant-based manufacturing facility in Brazil New facility for Bio-Manguinhos will use iBio's plant-based protein expression technology CHALFONT ST GILES, U.K. and NEWARK, Del., April 9, 2013 /PRNewswire/ -- GE Healthcare (NYSE: GE) and iBio, Inc. (NYSE MKT: IBIO), today announced GE Healthcare has signed a contract to design a new plant-based multipurpose manufacturing facility for Bio-Manguinhos/Fiocruz in Brazil. The design project is the first contract for the global alliance between GE Healthcare and iBio, announced in 2012. The alliance combines iBio's innovative plant-based manufacturing platform, iBioLaunchTM, with GE Healthcare's capabilities in process design and start-to-finish biopharmaceutical and vaccine manufacturing technologies. (Photo: photos.prnewswire.com/prnh/20130409/N... ) (Logo: photos.prnewswire.com/prnh/20120419/N... ) (Logo: photos.prnewswire.com/prnh/20120726/N... ) Bio-Manguinhos/Fiocruz is recognized internationally as a manufacturer of immunobiologicals for public health needs, primarily to support Brazilian Ministry of Health programs. It has invested in the development of bioprocess technologies such as iBioLaunch, through a co-development agreement with iBio and its research and development collaborator Fraunhofer USA Center for Molecular Biotechnology (FCMB), which will continue to play a key role in advancing iBioLaunch. Olivier Loeillot, General Manager of Enterprise Solutions at GE Healthcare said: "Vaccines are vital in the fight against global disease and we're pleased to be working with Bio-Manguinhos/Fiocruz on this important project. GE Healthcare's global capabilities and industry-leading expertise in biopharmaceutical manufacturing technologies, coupled with iBio's innovative technology and experience in plant-based protein expression, provide a solid foundation for this design project. By working closely with the team at Bio-Manguinhos/Fiocruz we will together design a state-of-the-art, technologically-advanced facility that's ready to meet the vaccine needs of tomorrow." Artur Couto, Director of Bio-Manguinhos/Fiocruz said: "In order to accomplish our mission and to meet the Brazilian Ministry of Health's demands, we are constantly investing in innovative technologies. The agreement with GE Healthcare is important because it will allow us to build a new facility based on a very innovative platform and address an important need of the Brazilian Ministry of Health." About GE Healthcare GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com. About iBio, Inc. iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator™ platform is complementary to the iBioLaunch platform and enables significantly improved vaccine products with higher potency and greater duration of effect. Further information is available at: www.ibioinc.com. About Bio-Manguinhos/Fiocruz Bio-Manguinhos is a techno-scientific unit of the Oswaldo Cruz Foundation (Fiocruz). Fiocruz is a centennial institution belonging to the Brazilian Ministry of Health with several institutes working on different health related areas (R&D, scientific information, history, education, manufacturing and health care). Bio-Manguinhos develops and manufactures vaccines, biotherapeutics and diagnostics to address the public health needs indicated by the Brazilian Ministry of Health. Currently, Bio-Manguinhos product list comprises 10 vaccines, 11 diagnostics and 2 bio therapeutics.
cost avg .45 geen trade maar een hold
- Veiliger dan andere productiemethodes - Sneller - Goedkoper Het is wel zo dat productiemethodes mede onderdeel zijn van approval processes.Daarna kan je er niet makkelijk mee switchen. Dus alles wat nu al op de markt is moet eerst weer langs de fda's van de wereld als productieproces anders word. Zal minder snel gebeuren. Voor nieuwe trajecten geld andersom ook.. alles wat met ibio platform ontwikkeld zal worden zal op dat platform gestoeld blijven ivm approval cycli.
Officiele PR vandaag iBio Pharmaceutical Technology Embraced by the Government of Brazil NEWARK, Del., June 24, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today released the following information, which was contained in the Portuguese language report published on June 18, 2013 in the official Journal of the Government of Brazil under the heading, "Brazil Expands Production of Biological Medicines." This information is being released in this translated form by iBio to assure uniform distribution to the public of material information regarding iBio. References to the "factory" refer to the facility described in iBio's press release dated April 9, 2013 and to the "first vaccine in the world from a plant," to the vaccine described in iBio's release dated January 18, 2011. (Logo: photos.prnewswire.com/prnh/20120419/N... ) "The ministry will invest U.S. $ 170 million in the construction of the first national factory of organic products made from plant cell technology unprecedented in the country, in Ceara." "The first technology platform for the production of biological medicines from plant cells, such as carrot and tobacco, involves partnerships between Fiocruz and the Israeli company Protalix, the American Fraunhofer USA Center for Molecular Biotechnology, and iBio Inc. This was also the first plant-based biotechnological which was registered in the Food and Drug Administration (FDA) and the National Agency for Sanitary Surveillance (ANVISA), worldwide. Operations should start at full steam in 2016. The new Fiocruz center will be installed in the city of Eusebio near Fortaleza (Ceara) and construction starts from 2014. A factory will initially produce drugs for rare diseases as Taliglucerase Alfa Recombinant Human, for Gaucher disease, and the first vaccine in the world from a plant, against yellow fever." "The production process from the extraction plant is a novelty in the country. The technology ensures higher security than the biological produced from viruses and bacteria. It produces fewer side effects and less resistance facing the human body which receives the treatment. Moreover, it requires less investment." "Ceara is very happy to help correct regional inequalities. It is the country's time to celebrate because we see investing in Brazil and seeing possibilities," said state governor Cid Gomes. "Organic products are more effective compared to traditional medicines from chemical synthesis, increasing the chances of successful treatment especially for chronic diseases. They are made from living material and manufactured from processes involving personalized medicine and molecular biology." "Currently biological resources represent 43% of the medicines used by the Ministry of Health, or about U.S. $ 4 billion per year." Full text of the original Portuguese language article is available at this link: www.jornaldebrasilia.com.br/site/noti...
Laatste maanden weer goed in de lift. Nog iemand meer die dit bedrijf volgt? Ze werden op de HAE-conference in Wenen vermeld. Heb nog niet veel info kunnen vinden behalve hun eigen website
stocktwits.com/symbol/IBIO Waarschijnlijk een hoop links om eens in te lezen.
Afgelopen vrijdag in de laatste 5 minuten +4% en nabeurs nog eens +6% Oorzaak van deze beweging wellicht onderstaand rapportwww.outsourcedpharma.com/doc/divine-o... Benieuwd wat het morgen gaat doen!
Best druk zo, hier in je eentje :) En dat terwijl in dit fonds een musthave vind in je bio-tech portefeuille. Gewoon een klein plukje. Het bedrijf is gebaseerd op een zeer innovatief platform.
finance.yahoo.com/news/ibio-inks-3d-b... Samenwerking met United therapeuticsfinance.yahoo.com/quote/UTHR?p=UTHR MarketCap van 3,5 miljard PreMarket deed het nieuws, IBIO al ruim 300% stijgen met enorme volumes. Ik snap er dan ook helemaal niets van dat dat dus terug zakt naar 80% bij openen van de beurs en gedurende de dag nog verder afzakt naar 35%. Ben erg benieuwd wat de koers de komende dagen gaat doen.
Ibio Inc (NYSEAMERICAN:IBIO) Gets Attention As Coronavirus Escalates By Tomas Scott - February 28, 2020 The coronavirus crisis has escalated quite significantly this week after plenty of fresh cases were discovered outside China. In such a situation, many companies that might be involved in creating a vaccine for the virus have seen their stocks soar. One such company is Ibio Inc (NYSEAMERICAN:IBIO), which made significant gains on Thursday and although there was no material news regarding the company, it seems that the rally may have been related to its coronavirus vaccine. The company had been working in collaboration with CC Pharming to develop a vaccine for the coronavirus, and it is believed that Ibio could be making an announcement about it soon. The stock is up another 123% at $1.93 in the pre-market session.oracledispatch.com/2020/02/28/ibio-in...
Ibio: Verdiep je erin en doe met de info wat je wilt:www.youtube.com/watch?v=a5mOTrs3DA0&a...
Zou deze nog verder stijgen denk je?
Ja ze hebben de mogelijkheid om 600 miljoen vaccines per jaar te produceren via eigen productie, dat is uniek. Als je kijk naar market cap zit er nog wel wat ruimte, denk voor augustus op 12-15 dollar...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
861,72
-0,42%
EUR/USD
1,0662
+0,17%
FTSE 100
7.834,95
-0,53%
Germany40^
17.741,10
-0,54%
Gold spot
2.379,82
+0,02%
NY-Nasdaq Composite
15.601,50
-0,52%
Stijgers
Dalers